Combination Therapy for Erectile Dysfunction

Abstract

The objective: to evaluate the efficacy and safety of using hormone replacement therapy with testosterone in combination with iFDE-5 (udenafil) in the treatment of erectile dysfunction (ED) in men with androgen deficiency associated with type 2 diabetes mellitus (DM).

Materials and methods. The study involved 20 patients with type 2 diabetes and signs of ED on the background of secondary hypogonadism. Before treatment, patients underwent a standard clinical examination in a urological hospital, after which they were equally divided into two groups using a «tossed coin». Patients of group I (n = 10) received testosterone HRT at a dose of 50 mg / day for 12 weeks, patients of group II (n=10) used testosterone hormone combined with udenafil (100–200 mg/day twice and more than once a week) also for 12 weeks.

Results. It was proved that after 12 weeks of therapy, the level of total testosterone in the combination therapy group increased from 6.6±1.3 to 17.1±4.2 nmol/ml, while in the monotherapy group the changes were less pronounced – from 5,6±1.2 to 13.3±2.3 nmol/ml. An important indicator for patients with type 2 diabetes – glucose level – also showed significant changes in the combination therapy group: from 10.2±2.7 to 6.9±1.6 mmol/l compared with the results of the monotherapy group: from 9,9±2.4 to 8.1±1.5 mmol/l.

Conclusion. Erectile dysfunction therapy in men with androgen deficiency in patients with type 2 diabetes with hormone replacement therapy with testosterone in combination with phosphodiesterase-5 inhibitor (udenafil) can be an effective alternative to traditional hormone replacement therapy, but further research is needed in this direction.